Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
08/2003
08/28/2003WO2003041731A3 Method to obtain protection against bystander allergen
08/28/2003WO2003030931A3 Vaccine against arthropod-borne infectious diseases
08/28/2003WO2003029289A3 Fragements of heat shock proteins and their use
08/28/2003WO2003016522A3 Methods and compounds for the targeting of protein to exosomes
08/28/2003WO2003014161A3 Antigen binding domains from fish
08/28/2003WO2003005957A3 Mutants of clostridium septicum alpha toxin and vaccines, antibodies, sera, and methods of treatment therewith
08/28/2003WO2002102990A3 Fibroblast growth factor and nucleic acid encoding same
08/28/2003WO2002097051A3 Protein arrays and methods and systems for producing the same
08/28/2003WO2002097044A3 Alternative splice forms of proteins as basis for multiple therapeutic modalities
08/28/2003WO2002094192A3 Antibodies against tumor necrosis factor delta (april)
08/28/2003WO2002092818A3 Streptococcus agalactiae genome sequence, use for developing vaccines, diagnostic tools, and for identifying therapeutic targets
08/28/2003WO2002088328A3 Method for generating highly active human dendritic cells from monocytes
08/28/2003WO2002081508A3 Use of cd25 binding molecules in steroid-resistant patients
08/28/2003WO2002078717A3 Compositions and methods for reducing rna virus pathogenicity
08/28/2003WO2002078603A3 Plasmodium falciparum erythrocyte binding protein baebl for use as a vaccine
08/28/2003WO2002077021A3 Streptococcus pneumoniae proteins and nucleic acids
08/28/2003WO2002074783A3 Modified interferon beta with reduced immunogenicity
08/28/2003WO2002074337A8 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
08/28/2003WO2002074048A8 P-glycoproteins and uses thereof
08/28/2003WO2002070006A3 Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
08/28/2003WO2002058622A3 Sn-38 lipid complexes and methods of use
08/28/2003WO2002054073A3 Latent human tuberculosis model, diagnostic antigens, and methods of use
08/28/2003WO2002043478A3 Transgenic transchromosomal rodents for making human antibodies
08/28/2003WO2002041921A3 Compositions for protection against bovine viral diseases
08/28/2003WO2002038174A3 Vaccines containing recombinant hantavirus proteins, methods for producing said vaccines and their use
08/28/2003WO2002036149A3 Methods for obtaining inhibitors of t-cell membrane protein (tirc7) ligand binding and uses thereof
08/28/2003WO2002028430A3 Treatment of juvenile rheumatioid arthritis by oral administration of pooled human immunoglobulin and an antacid
08/28/2003WO2002024876A3 Live influenza vaccine and method of manufacture
08/28/2003WO2002020050A3 Eiav p26 deletion vaccine and diagnostic
08/28/2003WO2002007752A3 Red blood cell as vehicle for agent-membrane translocation sequence conjugate
08/28/2003WO2002002780A3 Human serine-threonine kinase
08/28/2003WO2001092307A3 Therapeutic compounds for ovarian cancer
08/28/2003WO2000042994A3 Inhibition of bacterial dissemination
08/28/2003US20030163834 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of Erk-5
08/28/2003US20030162953 Chemically-defined non-polymeric valency platform molecules and conjugates thereof
08/28/2003US20030162821 Applying topical mixtures of allantoin, emulsifiers and optionally steroids, nonsteroidal antiinflammatory agents, leukotriene antagonists or monoclonal antibodies, to prevent scarring, ulcers or blisters on skins
08/28/2003US20030162796 Pharmaceutical composition for the treatment of disorders of non-human mammals
08/28/2003US20030162741 Oral DNA composition for hepatitis B virus chronic infection
08/28/2003US20030162738 Antigenic composition comprising a polycationic peptide and inosine and cytosine
08/28/2003US20030162733 Nucleic acid adjuvants
08/28/2003US20030162720 Therapeutic anti-HIV (IV9) compounds
08/28/2003US20030162715 Fertility; controlling cell differentiation
08/28/2003US20030162714 Modulate cell differentiation; muscular disorders; fat metabolism; bone disorders
08/28/2003US20030162709 Methods of generating multispecific, multivalent agents from VH and VL domains
08/28/2003US20030162274 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
08/28/2003US20030162263 Specific peptide of 6 to 40 amino acids and is capable of giving rise to antibodies which inhibit superantigen activity associated with HERV-K18 (human endogenous retrovirus) localized in intron 1 of CD48 gene on chromosome 1
08/28/2003US20030162260 Fusion proteins that includes an immune enhancing domain and an immunogenic domain
08/28/2003US20030162229 Immuno-interactive fragments of the alpha-C subunit of inhibin
08/28/2003US20030162223 Detection of insecticide; determination, calibration of binding to protein
08/28/2003US20030162208 Cloned leptospira outer membrane protein
08/28/2003US20030162167 Hepatitis c virusl detection using Dna sequences; liver disorders; immunoassay
08/28/2003US20030161889 Microspheres having diameter of 1 nanometer to 10 microns comprised of poly(DL-lactide-co-glycolide) as bulk matrix; immunogenic substance comprising Colony Factor Antigen or hepatitis B surface antigen
08/28/2003US20030161845 A chimeric Arterivirus composed of parts originating from at least two different arteriviruses where a stretch of nucleic acids encoding a non-Arteriviris protein fragment is inserted in the full genome; vaccines; veterinary medicine; swine
08/28/2003US20030161839 Elimination of contaminating proteins and conservation of the native folding and disulfide bridging by means of proper expression and purification of the MSP-142 3d7 allele; diagnosis, prophylactsis and therapy for malaria
08/28/2003US20030161838 A highly purified protein, Plasmodium falciparum MSP-142, which retains folding and disulfide bridging of the native molecule and is useful as a diagnostic reagent, antibody production, and as a vaccine for malaria
08/28/2003US20030161837 Crosslinking an immunoglobulin or fragment thereof with anN-hydroxyl-succinimide ester and a maleimide linked vis a polyethyleneoxide spacer and incubating with a polypeptide having a sulfhydryl group (an allergen or autoantigen)
08/28/2003US20030161836 Biological materials and methods useful in the diagnosis and treatment of diseases
08/28/2003US20030161835 Polypeptides from moraxella (branhamella) catarrhalis
08/28/2003US20030161834 Adjuvant compositions comprising a saponin and and an immunostimulatory oligonucleotide containing unmethylated CpG (a cytosine guanosine dinucleotide DNA motif); synergistic induction of antigen; anticarcinogenic agents
08/28/2003US20030161833 Chlamydia antigens and corresponding DNA fragments and uses thereof
08/28/2003US20030161832 Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen
08/28/2003US20030161827 Therapies that improve graft survival
08/28/2003US20030161826 Therapy for autoimmune disease; central nervous system disorders
08/28/2003CA2513192A1 Nucleotide sequence coding for a tolc and a defined amino acid sequence
08/28/2003CA2477195A1 Deleted sequence in m. tuberculosis, method for detecting mycobacteria using these sequences and vaccines
08/28/2003CA2477191A1 Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
08/28/2003CA2477068A1 Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue
08/28/2003CA2477012A1 Anti-a.beta. antibodies and their use
08/28/2003CA2476958A1 An immunological adjuvant
08/28/2003CA2476956A1 Strategy for retroviral immunotherapy
08/28/2003CA2476854A1 Surrogate antibodies and methods of preparation and use thereof
08/28/2003CA2476832A1 Use of an inhibitor or antagonist against tissue factor
08/28/2003CA2476764A1 Compositions and methods for surrogate antibody modulation of an immune response and transport
08/28/2003CA2476626A1 Microparticles with adsorbed polypeptide-containing molecules
08/28/2003CA2476625A1 Mhc-peptide complex binding ligands
08/28/2003CA2476451A1 Hyaluronic acid mediated adenoviral transduction
08/28/2003CA2473133A1 Rrp sequences and knockout mice and uses thereof
08/28/2003CA2473132A1 Vaccination and vaccine and drug delivery by topical application of vectors and vector extracts recombinant vectors, and noninvasive genetic immunization, expression products therefrom,and uses thereof
08/28/2003CA2380471A1 Oral dna vaccine composition for hepatitis b virus chronic infection
08/27/2003EP1338657A1 Sequences specifcally deleted from Mycobacterium tuberculosis genome and their use in diagnosistics and as vaccines
08/27/2003EP1338608A2 Protein complexes and methods for their use
08/27/2003EP1338607A2 Antigenic iron repressible proteins from n. meningitidis related to the heolysin family of toxins
08/27/2003EP1338606A1 Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer
08/27/2003EP1338198A1 Method of constructing mouse suitable for the take, differentiation and proliferation of heterogenous cells, mouse constructed by this method and use of the mouse
08/27/2003EP1337850A1 Method for diagnosing a tumor in a patient determining the concentration of pibf
08/27/2003EP1337647A2 Helicobacter cysteine rich protein a (hcpa) and uses thereof
08/27/2003EP1337641A2 Flea gaba receptor subunit nucleic acid molecules, proteins and uses thereof
08/27/2003EP1337640A2 NOVEL RETINA-SPECIFIC HUMAN PROTEINS C7orf9, C12orf7, MPP4 AND F379
08/27/2003EP1337634A2 Novel polypeptides involved in immune response
08/27/2003EP1337633A2 Anti-angiogenic proteins and fragments and methods of use thereof
08/27/2003EP1337560A2 Truncated cd200
08/27/2003EP1337558A2 A "bach" g protein coupled receptor polypeptide and polynucleotide encoding this receptor
08/27/2003EP1337556A2 Mutated immunogenic peptides derived from r9m, polynucleotides coding for same and therapeutic uses thereof
08/27/2003EP1337554A2 Novel compounds
08/27/2003EP1337553A2 Nucleic acid vaccine comprising a fusion protein including an adjuvant sequence from a plant viral coat protein
08/27/2003EP1337544A2 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme
08/27/2003EP1337276A2 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor
08/27/2003EP1337152A2 Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
08/27/2003EP1337149A2 Vaccine immunotherapy for immune suppressed patients
08/27/2003EP1183047B1 Pharmaceutical preparation
1 ... 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 ... 1823